Drugs / CYT-6091
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00356980 | May 2006 → Feb 2009 | cancer of unknown primary site | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CYT-6091 | “A novel nanomedicine, CYT-6091, constructed by simultaneously binding recombinant human tumor necrosis factor alpha (rhTNF) and thiolyated polyethylene glycol to the surface of...” PMID 20876255 ↗ Sep 2010 |
| Route | Intravenous | “CYT-6091, whose dosing was based on the amount of rhTNF in the nanomedicine, was injected intravenously” PMID 20876255 ↗ Sep 2010 |